DUBLIN–(BUSINESS WIRE)–The “Nordic Eyewear Market (Sweden, Denmark, Norway & Finland): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)” report has been added to ResearchAndMarkets.com’s offering. The Nordic eyewear market is…
Author: Business Wire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported it…
Nouveauté Suisse pour faciliter la sélection des lentilles dans la chirurgie de la cataracte
NEUCHÂTEL, Suisse–(BUSINESS WIRE)–La société Swiss Advanced Vision (SAV-IOL SA) a annoncé le lancement de nouvelles fonctionnalités pour son Calculateur torique, améliorant l’expérience globale de calcul. Pour la première fois, les ophtalmologues pou…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announce…
MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.
SAN DIEGO–(BUSINESS WIRE)–MediPrint® Ophthalmics, a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study. The Phase IIb trial was an act…
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
TORONTO–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpas…
Vivity, la LIO à profondeur focale accrue première au monde, atteint un million d’implants
TORONTO–(BUSINESS WIRE)–Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir brillamment, annonce aujourd’hui fièrement que les lentilles intraoculaires (LIO) à profondeur focale accrue…
Telios Pharma Announces Successful Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Disease
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Telios Pharma, Inc., a clinical stage biopharmaceutical company committed to improving the lives of patients with inflammatory diseases, today announced topline results from its Phase 2 study assessing TL-925, a f…
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
FORT WORTH, Texas–(BUSINESS WIRE)–Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
National Vision Holdings, Inc. Announces Participation in the UBS Global Consumer and Retail Conference
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) today announced that Reade Fahs, chief executive officer, and Melissa Rasmussen, chief financial officer, will participate in a fireside chat at the UBS Global Consumer and Reta…
STAAR Surgical to Participate in Two Upcoming Investor Conferences
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that manage…
SDC Optimizes Focus on Tech-Enabled Biometric Services
PHOENIX–(BUSINESS WIRE)–Statistics & Data Corporation (SDC), a global leader in life sciences biometrics services and technology solutions, announces a strategic decision to enhance focus and efficiency by transitioning its ophthalmic biometric d…
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will …
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday,…
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
CAMBRIDGE, England & NOTTINGHAM, England–(BUSINESS WIRE)–Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the data from a successful Phase I…
NVISION Eye Centers' Subsidiary, NVISION Clinical Research, Rapidly Expands Under New Leadership
ALISO VIEJO, Calif.–(BUSINESS WIRE)–NVISION Eye Centers, a renowned national leader in comprehensive eye care services, proudly announces the remarkable expansion of its subsidiary, NVISION Clinical Research, LLC. Spearheaded by the visionary leaders…
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. announces name change to Nordic Pharma, Inc. under new Nordic Group, B.V. ownership on March 4, 2024.
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quart…
GenSight Biologics annonce des communications scientifiques sur LUMEVOQ® au Congrès 2024 du NANOS
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central …